-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces Price Target of $270

Benzinga·12/09/2025 19:37:14
语音播报
Citigroup analyst Yigal Nochomovitz initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and announces Price Target of $270.